top of page

Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Not Allowed)

HHS-NIH11

Status:

Active

April 7, 2023

Posted:

Deadline: 

May 7, 2026

Funding

​

Program:

​

Award Floor:

Ceiling:

​

Match Required?

No

Eligibility

All

States:

Entity Types:

State governments, County governments, City or township governments, Special district governments, Independent school districts, Public & State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities, Native American tribal organizations, Nonprofits (with 501(c)(3) status), Nonprofits (without 501(c)(3) status)

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

This Funding Opportunity Announcement (FOA) invites research grant applications that propose the preclinical development of novel radioligands for positron emission tomography (PET) or single photon emission computed tomography (SPECT) imaging in rodent and nonhuman primate brain and incorporation of pilot or clinical feasibility evaluation in pre-clinical studies and appropriate model development. Projects proposing clinical assessments of novel radioligands should respond to FOA PAR XX-XXX .

Contact

Email:

grantsinfo@nih.gov

Phone:

​

Source Type:

Federal

Tired of searching for grants? Consider a Scouting Report.

bottom of page